![Implementing a centralised pharmacovigilance service in a non-commercial setting in the United Kingdom | Trials | Full Text Implementing a centralised pharmacovigilance service in a non-commercial setting in the United Kingdom | Trials | Full Text](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2F1745-6215-14-171/MediaObjects/13063_2012_Article_1347_Fig1_HTML.jpg)
Implementing a centralised pharmacovigilance service in a non-commercial setting in the United Kingdom | Trials | Full Text
![QurAlis Receives Clinical Trial Authorisation (CTA) in European Union (EU) for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS QurAlis Receives Clinical Trial Authorisation (CTA) in European Union (EU) for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS](https://mma.prnewswire.com/media/1624254/QurAlis_Horizontal_Color_Logo.jpg?p=facebook)
QurAlis Receives Clinical Trial Authorisation (CTA) in European Union (EU) for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS
![CT01: How to Gain and Maintain Approval for Clinical Research Under the EU Clinical Trials Directive | Zenosis – Learning for Life CT01: How to Gain and Maintain Approval for Clinical Research Under the EU Clinical Trials Directive | Zenosis – Learning for Life](https://zenosis.com/brands/zenosis/pix/9CT01_2.jpg)